|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/05/22 Nu Skin Enterprises, Inc. 10-Q 6/30/22 69:7.2M Broadridge Fin’l So… Inc |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.56M
2: EX-31.1 Certification -- §302 - SOA'02 HTML 26K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 26K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 20K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 20K
11: R1 Document and Entity Information HTML 72K
12: R2 Consolidated Balance Sheets (Unaudited) HTML 122K
13: R3 Consolidated Balance Sheets (Unaudited) HTML 27K
(Parenthetical)
14: R4 Consolidated Statements of Income (Unaudited) HTML 91K
15: R5 Consolidated Statements of Comprehensive Income HTML 49K
(Unaudited)
16: R6 Consolidated Statements of Comprehensive Income HTML 27K
(Unaudited) (Parenthetical)
17: R7 Consolidated Statements of Stockholders' Equity HTML 70K
(Unaudited)
18: R8 Consolidated Statements of Stockholders' Equity HTML 23K
(Unaudited) (Parenthetical)
19: R9 Consolidated Statements of Cash Flows (Unaudited) HTML 107K
20: R10 The Company HTML 23K
21: R11 Summary of Significant Accounting Policies HTML 37K
22: R12 Goodwill HTML 38K
23: R13 Debt HTML 39K
24: R14 Leases HTML 67K
25: R15 Capital Stock HTML 31K
26: R16 Fair Value and Equity Investments HTML 81K
27: R17 Income Taxes HTML 28K
28: R18 Derivatives and Hedging Activities HTML 47K
29: R19 Segment Information HTML 197K
30: R20 Commitments and Contingencies HTML 24K
31: R21 Acquisitions HTML 23K
32: R22 Restructuring HTML 24K
33: R23 Subsequent Events HTML 22K
34: R24 Summary of Significant Accounting Policies HTML 49K
(Policies)
35: R25 Summary of Significant Accounting Policies HTML 28K
(Tables)
36: R26 Goodwill (Tables) HTML 40K
37: R27 Debt (Tables) HTML 39K
38: R28 Leases (Tables) HTML 70K
39: R29 Fair Value and Equity Investments (Tables) HTML 79K
40: R30 Derivatives and Hedging Activities (Tables) HTML 46K
41: R31 Segment Information (Tables) HTML 195K
42: R32 The Company (Details) HTML 24K
43: R33 Summary of Significant Accounting Policies, HTML 26K
Reclassifications (Details)
44: R34 Summary of Significant Accounting Policies, HTML 25K
Inventory (Details)
45: R35 Summary of Significant Accounting Policies, HTML 24K
Revenue Recognition (Details)
46: R36 Goodwill (Details) HTML 41K
47: R37 Debt, 2018 Credit Agreement (Details) HTML 50K
48: R38 Debt, Credit Agreement (Details) HTML 56K
49: R39 Debt, Debt Facilities (Details) HTML 69K
50: R40 Leases (Details) HTML 109K
51: R41 Capital Stock, Net Income per Share (Details) HTML 23K
52: R42 Capital Stock, Dividends (Details) HTML 43K
53: R43 Capital Stock, Repurchase of Common Stock HTML 29K
(Details)
54: R44 Fair Value and Equity Investments, Fair Value HTML 74K
(Details)
55: R45 Fair Value and Equity Investments, Equity HTML 27K
Investments (Details)
56: R46 Income Taxes (Details) HTML 44K
57: R47 Derivatives and Hedging Activities, Fair Value of HTML 34K
Derivative Instruments on the Balance Sheet
(Details)
58: R48 Derivatives and Hedging Activities, Effect of Cash HTML 33K
Flow Hedge Accounting on Accumulated Other
Comprehensive Income (Details)
59: R49 Segment Information, Revenue by Segment (Details) HTML 67K
60: R50 Segment Information, Segment Contribution HTML 60K
(Details)
61: R51 Segment Information, Depreciation and Amortization HTML 59K
and Capital Expenditures (Details)
62: R52 Acquisitions (Details) HTML 70K
63: R53 Restructuring (Details) HTML 50K
64: R54 Subsequent Events (Details) HTML 32K
67: XML IDEA XML File -- Filing Summary XML 119K
65: XML XBRL Instance -- brhc10040182_10q_htm XML 1.85M
66: EXCEL IDEA Workbook of Financial Reports XLSX 113K
7: EX-101.CAL XBRL Calculations -- nus-20220630_cal XML 171K
8: EX-101.DEF XBRL Definitions -- nus-20220630_def XML 594K
9: EX-101.LAB XBRL Labels -- nus-20220630_lab XML 1.51M
10: EX-101.PRE XBRL Presentations -- nus-20220630_pre XML 946K
6: EX-101.SCH XBRL Schema -- nus-20220630 XSD 123K
68: JSON XBRL Instance as JSON Data -- MetaLinks 365± 528K
69: ZIP XBRL Zipped Folder -- 0001140361-22-028236-xbrl Zip 291K
| 1. |
I have reviewed this quarterly report on Form 10-Q of Nu Skin Enterprises, Inc.;
|
| 2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
| 3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
| 4. |
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
| (a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the
registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
| (b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
| (c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and
|
| (d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth
fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
| 5. |
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the
audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
| (a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s
ability to record, process, summarize and report financial information; and
|
| (b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
|
Date: August 4, 2022
|
||
|
Chief Executive Officer
|
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 8/5/22 | |||
| Filed on: | 8/4/22 | 8-K | ||
| For Period end: | 6/30/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/17/22 Nu Skin Enterprises, Inc. 8-K:1,2,9 6/14/22 11:1.7M Broadridge Fin’l So… Inc |